Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
Продолжение лечения тирзепатидом для поддержания снижения массы тела у взрослых с ожирением
2023-12-11
SCID: 54.1/ruwzm69g
Discuss with AI
obesityrandomized withdrawal trialtirzepatideweight maintenanceweight reduction
Figures from the paper
Abstract (AI)
Importance: The effect of continued treatment with tirzepatide on maintaining initial weight reduction is unknown. Objective: To assess the effect of tirzepatide, with diet and physical activity, on the maintenance of weight reduction. Design, Setting, and Participants: This phase 3, randomized withdrawal clinical trial conducted at 70 sites in 4 countries with a 36-week, open-label tirzepatide lead-in period followed by a 52-week, double-blind, placebo-controlled period included adults with a body mass index greater than or equal to 30 or greater than or equal to 27 and a weight-related complication, excluding diabetes. Interventions: Participants (n = 783) enrolled in an open-label lead-in period received once-weekly subcutaneous maximum tolerated dose (10 or 15 mg) of tirzepatide for 36 weeks. At week 36, a total of 670 participants were randomized (1:1) to continue receiving tirzepatide (n = 335) or switch to placebo (n = 335) for 52 weeks. Main Outcomes and Measures: The primary end point was the mean percent change in weight from week 36 (randomization) to week 88. Key secondary end points included the proportion of participants at week 88 who maintained at least 80% of the weight loss during the lead-in period. Results: Participants (n = 670; mean age, 48 years; 473 [71%] women; mean weight, 107.3 kg) who completed the 36-week lead-in period experienced a mean weight reduction of 20.9%. The mean percent weight change from week 36 to week 88 was -5.5% with tirzepatide vs 14.0% with placebo (difference, -19.4% [95% CI, -21.2% to -17.7%]; P < .001). Overall, 300 participants (89.5%) receiving tirzepatide at 88 weeks maintained at least 80% of the weight loss during the lead-in period compared with 16.6% receiving placebo (P < .001). The overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide and 9.9% for placebo. The most common adverse events were mostly mild to moderate gastrointestinal events, which occurred more commonly with tirzepatide vs placebo. Conclusions and Relevance: In participants with obesity or overweight, withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction. Trial Registration: ClinicalTrials.gov Identifier: NCT04660643.
Key Findings
1
After a 36-week tirzepatide lead-in, participants achieved a mean weight reduction of 20.9%.
2
At week 88, 89.5% of participants continuing tirzepatide maintained at least 80% of lead-in weight loss, compared with 16.6% switching to placebo.
3
Continuing tirzepatide for 52 additional weeks produced a 5.5% mean weight decrease, whereas switching to placebo produced a 14.0% increase.
4
Overall weight reduction from baseline to week 88 was 25.3% with continued tirzepatide versus 9.9% after switching to placebo; adverse events were mostly mild-to-moderate gastrointestinal events.
5
The between-group difference in weight change from weeks 36 to 88 was -19.4 percentage points (95% CI, -21.2% to -17.7%; P < .001).
Research Object
Adults with obesity (without diabetes) undergoing continued tirzepatide treatment with diet and physical activity
Research Subject
Maintenance of initial weight reduction during continued tirzepatide treatment versus withdrawal to placebo
Publication Details
Publication Date
2023-12-11
Journal
Publisher
ISSN
Cited by
971
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
Cited by6
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity2024
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity2025
Tirzepatide for Obesity Treatment and Diabetes Prevention2024
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review2024
Weight regain after cessation of medication for weight management: systematic review and meta-analysis2026
Patient perceptions of the efficacy and safety of tirzepatide: Discrepancies with clinical data and limited awareness of cardiovascular benefits2026